Mark Rigby

Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients

Journal of Clinical Investigation · 2015 · First of 27 authors · 254 citations

Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial

The Lancet Diabetes & Endocrinology · 2013 · First of 28 authors · Corresponding · 175 citations